Aurobindo Pharma has incurred higher consolidated net loss of Rs.128.91 crore during the first quarter ended June 2012 as against Rs.123.51 crore in the corresponding period of last year due to higher interest and depreciation provisions. Its EBDITA also declined by 17.1 per cent to Rs.141.97 crore from Rs.171.22 crore. With this loss, its earnings per share worked out negative Rs.4.43 as compared to negative Rs.4.20 in the last period.

The company's consolidated net sales increased by 12.4 per cent to Rs.1,197 crore from Rs.1,065 crore in the similar quarter of last year. The domestic sales increased by 4.9 per cent to Rs.349 crore from Rs.333 crore and exports increased by 16.5 per cent to Rs.811 crore from Rs.696 crore. Its formulation sales grew by 5.1 per cent to Rs.655 crore from Rs.623 crore and APIs sales improved by 27.9 per cent to Rs.587 crore from Rs.459 crore. The company's US sales improved by 19.8 per cent to Rs.328 crore from Rs.274 crore. Its sales in Europe and Rest of World improved by 35.8 per cent to Rs.186 crore from Rs.137 crore. The dossier income declined sharply by 64 per cent to Rs.6.8 crore from Rs.18.9 crore.

N Govindarajan, managing director, said, “While we have recorded growth on our top line, high cost of manufacturing like power and fuel, etc., has impacted our operating profits. However, we are positive that planned new formulation product launches along with growing business of high value APIs in advanced markets are expected to augment our operational profitability as the year progresses.”

The company filed nine ANDAs in USA during the quarter under review and total filings reached at 248. It filed 31 dossier in Europe and its cumulative filings reached at 1289. Its cumulative approvals in USA stood at 152, Australia 31, Canada 18 and South Africa 50 as at the end of June 2012.